Hisamitsu Miyaaki

20PUBLICATIONS
57CO-AUTHORS
Exercise physiologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Metabolic medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 08, 2026
The Five-Time Chair Stand Test Identifies Patients With Liver Cirrhosis at High Mortality Risk Overlooked by Conventional Sarcopenia Criteria.

|Feb 09, 2026
Post-to Pretreatment Ratio of Serum CXCL10 Level Predicts Short-Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct-Acting Antiviral Therapy.

Takanori Suzuki, Kentaro Matsuura, Yuki Tahata

|Dec 19, 2025
Plasma Vascular Endothelial Growth Factor-A Identified by Proximity Extension Assay Predicts Early Progression in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.

Kazuaki Tajima, Satoshi Miuma, Ryu Sasaki

|Nov 28, 2025
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Ryu Sasaki, Shigeo Shimose, Issei Saeki

|Nov 14, 2025
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Takanori Ito, Shigeo Shimose, Issei Saeki

|Sep 18, 2025
Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination.

Yuta Myojin, Hayato Hikita, Yuki Tahata

Pageof 4

Frequent Collaborators

10 joint publications

Ryu Sasaki

6 joint publications

Taro Takami

6 joint publications

Shigeo Shimose

5 joint publications

Takumi Kawaguchi